You're misstating the conclusions of that paper. The higher risk for young people only applies to Moderna and the comparison only compares myocarditis, while fo

You're misstating the conclusions of that paper. The higher risk for young people only applies to Moderna and the comparison only compares myocarditis, while for a full risk/benefit analysis you need to compare all outcomes. There are countries that only use Biontech for younger people, which is a reasonable way to deal with this if you have plenty of vaccine available.